By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – XDx today said that Highmark, a health insurer that covers around 4.8 million lives in Pennsylvania and West Virginia, is now covering its AlloMap test for beneficiaries of the health plan.

The AlloMap test is a gene expression-based assay used to aid the monitoring of heart transplant rejection. The test measures the expression levels of 20 genes from a blood sample to provide a score that is used by clinicians to help evaluate the risk of transplant rejection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene regulation changes linked to human brain evolution, and more.

The New York Stem Cell Foundation's Initiative on Women in Science and Engineering working group presents seven strategies to promote gender equality in the sciences.

Researchers link a genetic variation to the ability to quickly process arsenic in people living in the Andes Mountains.

A small portion of pregnant women who've undergone non-invasive prenatal testing have found out from the test that they have cancer.